文献速递白血病

新诊断TP53突变急性髓系白血病选择低甲基化药物的COMMAND注册研究

Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study.
PubMed 文献 · Leukemia · 2026-08-31

本研究为多中心回顾性分析,比较地西他滨(DEC)与阿扎胞苷(AZA)为基础的诱导方案在新诊断TP53突变急性髓系白血病(TP53-MT AML)中的疗效。652例患者中321例接受HMA诱导(DEC 183例,AZA 138例),倾向评分匹配后两组EFS(P=0.920)和OS(P=0.927)无显著差异。多打击TP53状态独立与更差EFS和OS相关。

要点

  • DEC与AZA为基础诱导在TP53-MT AML中生存结局相当。
  • 多打击TP53状态独立预测更差EFS和OS。
  • 联合VEN方案间未观察到显著两两差异。

核心结论

  • AZA与DEC为基础诱导在TP53-MT AML中产生可比生存结局。

研究设计与样本

  • 多中心回顾性分析纳入652例新诊断TP53-MT AML,其中321例接受HMA诱导(DEC 183例,AZA 138例)。

主要发现

  • 倾向评分匹配队列中EFS(P=0.920)和OS(P=0.927)无显著差异。
  • DEC+VEN、AZA+VEN、DEC、AZA中位EFS分别为5.1、3.4、5.9、5.6个月,12个月EFS率分别为24%、17%、18%、16%。
  • DEC+VEN、AZA+VEN、DEC、AZA中位OS分别为5.7、7.1、9.2、7.1个月,12个月OS率分别为31%、23%、29%、32%。
  • TP53突变亚型与结局无关,多打击TP53状态独立与更差EFS和OS相关。

临床怎么用

  • 在TP53-MT AML中,AZA与DEC为基础诱导可互换选择,无需因TP53状态偏好某一HMA。
  • 多打击TP53状态可用于风险分层,提示更差生存。

局限性

  • 回顾性设计可能引入选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although azacitidine (AZA) and decitabine (DEC) demonstrate comparable efficacy in AML, prior data suggest that DEC may induce deeper TP53 mutation clearance and higher response rates; however, direct comparisons in TP53-mutant (TP53-MT) AML are lacking. We conducted a large multicenter retrospective analysis to compare outcomes between DEC- and AZA-based induction, including combinations with venetoclax (VEN). Of 652 patients with newly diagnosed TP53-MT AML, 321 received HMA-based induction (DEC, n = 183; AZA, n = 138). Baseline clinical and genomic characteristics were comparable between the DEC and AZA groups. TP53 mutation subtype were not associated with outcomes, whereas multi-hit TP53 status was independently associated with inferior EFS and OS. In the propensity score-matched cohort, no significant differences in event-free survival (EFS; P = 0.920) or overall survival (OS; P = 0.927) were observed. Median EFS was 5.1, 3.4, 5.9, and 5.6 months, with 12-month estimates of 24%, 17%, 18%, and 16%, while median OS was 5.7, 7.1, 9.2, and 7.1 months, with corresponding 12-month OS rates of 31%, 23%, 29%, and 32% for DEC + VEN, AZA + VEN, DEC, and AZA, respectively. No significant pairwise differences were observed between regimens. These findings from a large multicenter cohort suggest that AZA- and DEC-based induction yield comparable survival outcomes in TP53-MT AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Badar T, Foran J, Jamy O, et al. Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study. Leukemia. 2026. PMID: 42675141. doi:10.1038/s41375-026-03119-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。